

Wenxiang Wang*, Jiahui Mou and Yue Sun

The crystal structure of ethyl 7-ethyl-5-methyl-4,7-dihydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate, C₁₀H₁₅N₅O₂




Table 1: Data collection and handling.

Crystal:	Colorless prism
Size:	0.36 × 0.16 × 0.14 mm
Wavelength:	MoK α radiation (0.71073 Å)
μ :	0.09 mm ⁻¹
Diffractometer, scan mode:	Rigaku SCXmini, ω
$\theta_{\max}$, completeness:	27.5°, >99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$:	6372, 2794, 0.034
R_{int} :	
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 1667
$N(\text{param})_{\text{refined}}$:	157
Programs:	Rigaku [1], Olex2 [2], SHELX [3, 4], Diamond [5]

Source of materials

In a 25 mL reaction vessel, a solution of propionaldehyde (10 mmol), ethyl 3-oxobutanoate (10 mmol), and 5-aminotetrazole (10 mmol) in 7.5 mL propane-1,2-diol and 2 mL water was sealed, and kept at 120 °C for 12 h before it was cooled to room temperature. The reaction solution was poured into 50 mL distilled water, stirred vigorously for 10 min, and then the solid of crude tetrazolopyrimidine was filtered out. Recrystallization with methanol and DMF gave the crystal product. **IR** (KBr, ν , cm⁻¹) for C₁₀H₁₅N₅O₂: 3475, 3247, 3176, 3100, 2947, 2932, 1707, 1651, 1574, 1450, 1318, 1262, 1227, 1150, 1095, 1018, 990, 878, 844, 788, 672, 565, 472 [8]. **¹H NMR** (300 MHz, CDCl₃) (δ , ppm) for C₁₀H₁₅N₅O₂: 11.08(s, 1H, NH), 5.82(s, 1H, CH), 4.26(s, 2H, CH₂), 2.62(s, 3H, CH₃), 2.08(s, 1H, CH₂), 1.88(s, 1H, CH₂), 1.34(s, 3H, CH₃), 0.80(s, 3H, CH₃) [9]. **ESI-MS** for C₁₀H₁₅N₅O₂[(M-1)⁻]: 236.46.

Experimental details

All the hydrogen atoms were calculated geometrically and with C–H distances ranging from 0.96 to 0.98 Å, with $U_{\text{iso}}(\text{H}) = 1.2\text{--}1.5U_{\text{eq}}(\text{C})$. N–H = 0.86 Å, with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{N})$.

<https://doi.org/10.1515/ncrs-2022-0471>

Received September 23, 2022; accepted October 27, 2022;
published online November 10, 2022

Abstract

C₁₀H₁₅N₅O₂, triclinic, $P\bar{1}$ (no. 2), $a = 8.0501(16)$ Å, $b = 8.6163(17)$ Å, $c = 9.6654(19)$ Å, $\alpha = 69.74(3)^\circ$, $\beta = 75.79(3)^\circ$, $\gamma = 87.43(3)^\circ$, $V = 609.1(2)$ Å³, $Z = 2$, $R_{\text{gt}}(F) = 0.0593$, $wR_{\text{ref}}(F^2) = 0.1821$, $T = 293$ K.

CCDC no.: 805968

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

*Corresponding author: Wenxiang Wang, Jiangsu Vocational Institute of Architectural Technology, Xuzhou 221116, P. R. China, E-mail: wxwang_1109@163.com. <https://orcid.org/0000-0001-7297-3387>

Jiahui Mou and Yue Sun, Jiangsu Vocational Institute of Architectural Technology, Xuzhou 221116, P. R. China. <https://orcid.org/0000-0002-3398-5550> (Y. Sun)

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	<i>U</i> _{iso} [*] / <i>U</i> _{eq}
O1	0.2143 (3)	−0.0977 (2)	−0.0208 (2)	0.0810 (6)
O2	0.2386 (2)	0.17728 (19)	−0.13123 (17)	0.0613 (5)
N1	0.3790 (2)	−0.0114 (2)	0.3407 (2)	0.0510 (5)
H1	0.381700	−0.087596	0.425638	0.061*
N2	0.5110 (2)	0.2062 (2)	0.3884 (2)	0.0534 (5)
N3	0.5291 (3)	0.3720 (2)	0.3096 (2)	0.0650 (6)
N4	0.4616 (3)	0.4124 (2)	0.1947 (2)	0.0619 (6)
N5	0.3968 (2)	0.26838 (19)	0.19599 (19)	0.0465 (5)
C1	0.3115 (3)	−0.2336 (3)	0.2645 (3)	0.0639 (7)
H1A	0.267821	−0.255143	0.188694	0.096*
H1B	0.235484	−0.285120	0.362843	0.096*
H1C	0.423139	−0.277980	0.264019	0.096*
C2	0.3243 (3)	−0.0501 (2)	0.2301 (2)	0.0450 (5)
C3	0.2910 (2)	0.0717 (2)	0.1086 (2)	0.0429 (5)
C4	0.2454 (3)	0.0358 (3)	−0.0168 (3)	0.0511 (6)
C5	0.2969 (3)	0.2544 (2)	0.0916 (2)	0.0496 (6)
H5	0.357781	0.318492	−0.012910	0.059*
C6	0.1201 (4)	0.3247 (3)	0.1267 (4)	0.0792 (9)
H6A	0.135169	0.441321	0.110442	0.095*
H6B	0.058023	0.316591	0.055050	0.095*
C7	0.0121 (4)	0.2404 (4)	0.2860 (4)	0.0990 (11)
H7A	−0.000446	0.124075	0.304976	0.149*
H7B	−0.098979	0.286977	0.296298	0.149*
H7C	0.066917	0.256673	0.357906	0.149*
C8	0.4279 (3)	0.1465 (2)	0.3140 (2)	0.0431 (5)
C9	0.1833 (3)	0.1674 (3)	−0.2597 (3)	0.0629 (7)
H9A	0.071200	0.111089	−0.225923	0.076*
H9B	0.263831	0.106900	−0.312147	0.076*
C10	0.1757 (4)	0.3407 (4)	−0.3626 (3)	0.0843 (9)
H10A	0.093509	0.398292	−0.310088	0.126*
H10B	0.142096	0.339835	−0.450999	0.126*
H10C	0.286641	0.395780	−0.393031	0.126*

Comment

Tetrazolo[1,5-*a*]pyrimidines and their partially hydrogenated derivatives are very important chemical intermediates [6]. To address green chemistry principles for the synthesis of dihydro tetrazolo pyrimidines, one may concern carrying out these reactions under solvothermal conditions with propane-1,2-diol and water as mixture solvents [7].

There is one crystallographically independent molecule in the asymmetric unit. Almost all non-hydrogen atoms are coplanar except C(6) and C(7) from propionaldehyde [10]. Distance between N1–C2 (1.393 Å) is shorter than C5–N2 (1.473 Å). The tetrazole conjugated system extends to C3 from N1. The pyrimidine ring is in a flattened boat conformation [11]. Two adjacent molecules are connected by N(1)–H...N(2) intermolecular hydrogen bonds. Bond lengths and angles are as expected [12–14].

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Rigaku. *CrystalClearSM Expert*; Rigaku Corporation: Tokyo, Japan, 2005.
2. Bourhis L. J., Dolomanov O. V., Gildea R. J., Howard J. A. K., Puschmann H. The anatomy of a comprehensive constrained, restrained refinement program for the modern computing environment—olex2 dissected. *Acta Crystallogr.* 2015, *A71*, 59–75.
3. Sheldrick G. M. *SHELXT* – integrated space-group and crystal structure determination. *Acta Crystallogr.* 2015, *A71*, 3–8.
4. Sheldrick G. M. Crystal structure refinement with *SHELXL*. *Acta Crystallogr.* 2015, *C71*, 3–8.
5. Brandenburg K. *DIAMOND. Visual Crystal Structure Information System. Ver. 4.0*; Crystal Impact: Bonn, Germany, 2015.
6. Shaik A., Shaik F. B., Tangella N. P., Veera B. G., Vadiga S. K., Naveen M. An efficient, multicomponent, green protocol to access 4, 7-dihydro-tetrazolo [1, 5-*a*] pyrimidines and 5, 6, 7, 9-tetrahydro-tetrazolo[5, 1-*b*]quinazolin-8(4*H*)-ones using PEG-400 under microwave irradiation. *Synth. Commun.* 2019, *49*, 3181–3190.
7. Wang W. X., Cai H. L., Xiong R. G. Hydrothermal synthesis method of 5-(4'-methylbiphenyl-2-yl)-1*H*-tetrazole. *Chin. Chem. Lett.* 2013, *24*, 783–785.
8. Kour P., Singh V. P., Khajuria B., Singh T., Kumar A. Al (III) chloride catalyzed multi-component domino strategy: synthesis of library of dihydro-tetrazolo[1, 5-*a*]pyrimidines and tetrahydro-tetrazolo[1, 5-*a*]quinazolinones. *Tetrahedron Lett.* 2017, *58*, 4179–4185.
9. Irina G. T., Sergey A. K., Vladimir I. M., Svitlana V. S., Viktoriya V. D., Vladimir N. S., Mikhail V. D., Valentyn A. C., Sergey M. D. In water multicomponent synthesis of low-molecular-mass 4, 7-dihydro-tetrazolo[1, 5-*a*]pyrimidines. *Beilstein J. Org. Chem.* 2019, *15*, 2390–2397.
10. Fang B., Meng J. P., Luo Y. Crystal structure of methyl 2-(4-(pyrazolo[1, 5-*a*] pyrimidin-6-yl)phenyl)acetate, C₁₅H₁₃N₃O₂. *Z. Kristallogr. N. Cryst. Struct.* 2019, *234*, 395–396.
11. Shen S. D., Feng X. D., Yang W. H., Yao C. S. Ethyl 7-(4-bromophenyl)-5-trifluoromethyl-4, 7-dihydro-tetrazolo[1, 5-*a*] pyrimidine-6-carboxylate. *Acta Crystallogr.* 2010, *E66*, o2421.
12. Price I. K., Rougeot C., Hein J. E. Crystal structure of 5, 7-diphenyl-4, 7-dihydro-tetrazolo[1, 5-*a*]pyrimidine. *Acta Crystallogr.* 2015, *E71*, o220.
13. Wang W. The crystal structure of ethyl 5-methyl-7-(4-(phenylthio)phenyl)-4, 7-dihydro-tetrazolo[1, 5-*a*] pyrimidine-6-carboxylate, C₂₀H₁₉N₅O₂S. *Z. Kristallogr. N. Cryst. Struct.* 2021, *236*, 781–783.
14. Haleel A. K., Rafi U. M., Jayathuna M. A., Rahiman A. K. Theoretical, single crystal and molecular docking analysis of tetrazolo[1, 5-*a*] pyrimidine-6-carboxylate derivatives. *J. Mol. Struct.* 2022, *1250*, 131706.